Imagen de Portada

Computer‐Aided Algorithmic Approaches to Drug Development for Multi‐Mutant HIV‐1 Reverse Transcriptase

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Akmal Zubair, Muhammad Ali, Mahmoud M. Hessien
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Clinical Pharmacology in Drug Development
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
por: Chenna Keshava Reddy Sannala, et al.
Publicado: (2024)

The Work Behind the First Dose: How Early Clinical Studies Shape the Course of Drug Development
por: Amalia M. Issa
Publicado: (2026)

Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach
por: Michiel de Vries, et al.
Publicado: (2024)

Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug‐Drug Interactions in Healthy Participants
por: Jianke Li, et al.
Publicado: (2024)

Phase 1 Evaluation of the Bioequivalence and Drug‐Drug Interaction Potential of a Novel Fixed‐Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine
por: Hyung Soon Lim, et al.
Publicado: (2024)

A Phase 1 Study to Evaluate the Pharmacokinetic Drug‐Drug Interaction Between Islatravir and Methadone in Participants on Stable Methadone Therapy
por: Randolph P. Matthews, et al.
Publicado: (2024)

A Phase 1 Dose‐Escalation, Food Effect, and Drug–Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR‐1505, in Healthy Volunteers
por: Vipul K. Gupta, et al.
Publicado: (2026)

A Drug‐Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2‐ and MATE1‐Mediated Transport of Metformin in Healthy Participants
por: Rajinder Bhardwaj, et al.
Publicado: (2024)

Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs
por: Kelong Han, et al.
Publicado: (2025)

Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study
por: Ramesh Boinpally, et al.
Publicado: (2024)

Editorial: Early Phase Innovation—Adapting to the New Age of Accelerated Drug Approvals
por: Amalia M. Issa
Publicado: (2025)

Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
por: Hongxia Jia, et al.
Publicado: (2025)

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants
por: Matthias Hoch, et al.
Publicado: (2025)

Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants
por: Shichang Miao, et al.
Publicado: (2024)

Comparative Pharmacokinetics and Safety Assessment of 1st‐ and 2nd‐Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover Study
por: Tu H. Mai, et al.
Publicado: (2024)

Physiologically Based Pharmacokinetic Modeling to Evaluate Drug‐Drug Interactions of Tacrolimus With Ritonavir, a CYP3A Irreversible Inhibitor: Applications for Dosing Optimization in Transplant Patients
por: Yanjun Jiang, et al.
Publicado: (2025)

A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer
por: Michael J. Hanley, et al.
Publicado: (2025)

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV
por: Kelong Han, et al.
Publicado: (2025)

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Recombinant Neorudin, a New Anticoagulant Drug in Patients With Acute Coronary Syndrome
por: Yu‐bin Liu, et al.
Publicado: (2024)

Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
por: Shintaro Nakayama, et al.
Publicado: (2024)

A Randomized, Cross‐Over Study Investigating the Comparability of Somatrogon‐ghla in 2 Different Drug Product Presentations
por: Allison Manners, et al.
Publicado: (2024)

Impact of Sampling Window Variability on Pharmacokinetic Parameters Estimated by Non‐Compartmental Analysis: Case Studies of Various Types of Drugs
por: Kyosuke Takahashi, et al.
Publicado: (2026)

Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate
por: Tim Tippin, et al.
Publicado: (2024)

Concentration–QTc Modeling to Support Clinical Development of Fezolinetant
por: Jace C. Nielsen, et al.
Publicado: (2025)

Pharmacokinetics of Fipaxalparant, a Small‐Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers
por: Yang Song, et al.
Publicado: (2024)

Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants
por: Jo Collier, et al.
Publicado: (2026)

A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti‐Wolbachia Candidate Macrofilaricide
por: Graham Devereux, et al.
Publicado: (2024)

Optimization of Romiplostim Biosimilar Efficacy Trial Using In Silico Clinical Trial Approach for Patients With Immune Thrombocytopenia
por: Aleksandr Petrov, et al.
Publicado: (2024)

A 2‐Part, Open‐Label, Phase 1 Bioequivalence and Food‐Effect Study of Ubrogepant in Healthy Adult Participants
por: Ramesh Boinpally, et al.
Publicado: (2025)

Pharmacokinetics, Safety, and Tolerability of a Single 5‐Day Treatment of Tirbanibulin Ointment 1% in 100 cm2: A Phase 1 Maximal‐Use Trial in Patients with Actinic Keratosis
por: Janet DuBois, et al.
Publicado: (2024)

The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
por: Nila Ganamurali, et al.
Publicado: (2026)

Comparative Bioequivalence Study of 2 Fixed‐Dose Combinations of Vildagliptin and Metformin at a Tablet Strength of 50/1000 mg in Moroccan Volunteers
por: Salma Lazrak, et al.
Publicado: (2025)

Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed‐Dose Combination Product: Phase 1 Results in Healthy Pre‐ and Postmenopausal Women
por: Mong‐Jen Chen, et al.
Publicado: (2024)

Bioequivalence Between a Gantenerumab Disposable Syringe and an Autoinjector: A Randomized Controlled Trial in Healthy Volunteers
por: Dietmar Schwab, et al.
Publicado: (2026)

Integrating Pharmacogenomic Insights in GLP‐1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management
por: Navodi Sandamini Jayathilaka, et al.
Publicado: (2025)

Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open‐Label, Crossover Study in Fasting Healthy Volunteers
por: Kar Ming Yee, et al.
Publicado: (2025)

Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease
por: Michael Babcock, et al.
Publicado: (2024)

Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
por: Panli Cardona, et al.
Publicado: (2024)

From Bench to Bedside and Beyond: Shaping the Future of Early‐Phase Clinical Pharmacology at CPDD
por: Amalia M. Issa
Publicado: (2025)

From Reflection to Acceleration: Clinical Pharmacology’s 2025 Lessons and 2026 Opportunities
por: Amalia M. Issa
Publicado: (2026)